Skip to main content
SpringerLink
Log in

Introduction to Diagnosis and Treatment in Pancreatic Neoplasms

  • Chapter
  • First Online:
Recent Innovations in Surgical Procedures of Pancreatic Neoplasms

  • 213 Accesses

Abstract

The key points in the diagnosis and treatment of pancreatic cancer are:

  • Molecular diagnosis: toward the early diagnosis. The in-depth study of mutations and their early detection, as well as markers such as microRNA, CTC, cfDNA, or exosomes, may provide new therapeutic targets.

  • Radiomics: toward a better definition and prognostic. CT radiomic evaluation using clinical data, biomarkers, and tissular features to develop predictive models for local recurrence and overall survival.

  • Medical treatment: personalized and precise. Although the implementation of FOLFIRINOX improved the results of monotherapy, they are still substantially inferior to other tumors. For greater therapeutic impact, it is essential to distinguish drug effectiveness markers that ensure a high level of permeation in the neoplastic tissue.

  • The surgical approach as a guarantor of the locoregional eradication. Navigation tools, incorporated progressively, must be key to achieving radical goals in both open and laparoscopic or robotic surgery. The intraoperative incorporation of radiomics with its developments of artificial intelligence and machine learning, together with the current fluorescence, should provide important advances to carry out the surgical approach of each patient in a personalized way.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. https://www.diariomedico.com/2014/11/13/areacientifica/especialidades/oncologia/investigacion/nihilismo-es-tonica-actual-cancer-pancreas

  2. https://gco.iarc.fr/today/data/factsheets/cancers/13-Pancreas-fact-sheet.pdf

  3. World Health Organization. World cancer report 2020.

    Google Scholar 

  4. Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019;10:10–27.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.

    Article  PubMed  Google Scholar 

  6. Solomon S, Das S, Brand R, Whitcomb DC. Inherited pancreatic cancer syndromes. Cancer J. 2012;18:485–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Greer JB, Whitcomb DC, Brand RE. Genetic predisposition to pancreatic cancer: a brief review. Am J Gastroenterol. 2007;102:2564–9.

    Article  CAS  PubMed  Google Scholar 

  8. National Comprehensive Cancer Network. NCCN Guidelines for Treatment of Cancer by Site. Available online: https://www.nccn.org/professionals/physician_gls/default.aspx#site

  9. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Morris JPT, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer. 2010;10:683–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Zhao F, Wei C, Cui M-Y, Xia Q-Q, Wang S-B, Zhang Y. Prognostic value of microRNAs in pancreatic cancer: a meta-analysis. Aging. 2020;12:9380–404.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:1039.

    Article  CAS  PubMed  Google Scholar 

  13. Zhang X, Shi S, Zhang B, Ni Q, Yu X, Xu J. Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes. Am J Cancer Res. 2018;8:332–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Liu X, Li C, Li J, Yu T, Zhou G, Cheng J, Li G, Zhou Y, Lou W, Wang X, Gong G, Liu L, Che Y. Detection of CTCs in portal vein was associated with intrahepatic metastases and prognosis in patients with advanced pancreatic cáncer. J Cancer. 2018;9:2038–45.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Earl J, Garcia-Nieto S, Martinez-Avila JC, Montans J, Sanjuanbenito A, Rodríguez-Garrote M, Lisa E, Mendía E, Lobo E, Malats N, Carrato A, Guillen-Ponce C. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cáncer. BMC Cancer. 2015;15:797–807.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Padillo J, Pereira S, Villanueva P, Suarez G, Marin L, Bernal C, Cepeda C, Beltran P, Alamo JM, Gomez MA, Muntane J. CTSs evaluation as prognostic marker in pancreatic cancer. Portal vein versus peripheral blood sample determination. ISLB Meeting 2020.

    Google Scholar 

  17. Young M, Wagner P, Ghosh S, Rinaudo JA, Baker SG, Zaret KS, Goggins M, Srivastava S. Validation of biomarkers for early detection of pancreatic cáncer: summary of the Allience of Pancreatic Cancer Consortia for workshop. Pancreas. 2018;47:135–41.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout R, Granton P, Zegers CML, Gillies R, Boellard R, Dekker A, Aerts HJW. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48:441–6.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Kato S, Honda K. Use of biomarkers and imaging for early detection of pancreatic cancer. Cancers. 2020;12:1965.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Jiang Y, Yuan Q, Lv W, Xi S, Huang W, Sun Z, Chen H, Zhao L, Liu W, Hu Y, Lu L, Ma J, Li T, Yu J, Wang Q, Li G. Radiomic signature of (18)F fluorodeoxyglucose PET/CT for prediction of gastric cancer survival and chemotherapeutic benefits. Theranostics. 2018;8:5915–28.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Yang L, Gu D, Wei J, Yang C, Rao S, Wang W, Chen C, Ding Y, Tian J, Zeng M. A radiomics nomogram for preoperative prediction of microvascular invasion in hepatocellular carcinoma. Liver Cancer. 2019;8:373–86.

    Article  CAS  PubMed  Google Scholar 

  22. Ma X, Wei J, Gu D, Zhu Y, Feng B, Liang M, Wang S, Zhao X, Tian J. Preoperative radiomics nomogram for microvascular invasion prediction in hepatocellular carcinoma using contrast-enhanced CT. Eur Radiol. 2019;29:3595–605.

    Article  PubMed  Google Scholar 

  23. Khalvati F, Zhang Y, Baig S, Lobo-Mueller EM, Karanicolas P, Gallinger S, Masoom A. Haider prognostic value of CT radiomic features in resectable pancreatic ductal adenocarcinoma. Sci Rep. 2019;9:5449.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Permuth JB, Choi J, Balarunathan Y, Kim J, Chen D-T, Chen L, Orcutt S, Doepker MP, Gage K, Zhang G, Latifi K, Hoffe S, Jiang K, Coppola D, Centeno BA, Magliocco A, Li Q, Trevino J, Merchant N, Gillies R, Malafa M, Florida Pancreas Collaborative. Combining radiomic features with a miRNA classifier may improve prediction of malignant pathology for pancreatic intraductal papillary mucinous neoplasms. Oncotarget. 2016;7:85785–97.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Polk SL, Choi JW, McGettigan MJ, Rose T, Ahmed A, Kim J, Jiang K, Balagurunathan Y, Qi J, Farah PT, Rathi A, Permuth JB, Jeong D. Multiphase computed tomography radiomics of pancreatic intraductal papillary mucinous neoplasms to predict malignancy. World J Gastroenterol. 2020;26:3458–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Cozzi L, Comito T, Fogliata A, Franzese C, Franceschini D, Bonifacio C, Tozzi A, Di Brina L, Clerici E, Tomatis S, Reggiori G, Lobefalo F, Stravato A, Mancosu A, Zerbi A, Sollini M, Kirienko M, Chiti A, Scorsetti M. Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma. PLoS One. 2019;14(1):e0210758. https://doi.org/10.1371/journal.pone.0210758.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Parr E, Du Q, Zhang C, Lin C, Kamal A, McAlister J, Liang X, Bavitz K, Rux G, Hollingsworth M, Baine M, Zheng D. Radiomics-based outcome prediction for pancreatic cancer following stereotactic body radiotherapy. Cancers. 2020;12:1051.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Tang T-Y, Li X, Zhang Q, Guo C-X, Zhang X-Z, Lao M-Y, Shen Y-N, Xiao W-B, Ying S-H, Sun K, Yu R-S, Gao S-L, Que R-S, Chen W, Huang D-B, Pang P-P, Bai X-L, Liang T-B. Development of a novel multiparametric MRI radiomic nomogram for preoperative evaluation of early recurrence in resectable pancreatic cancer. J Magn Reson Imaging. 2020;52:231–45.

    Article  PubMed  Google Scholar 

  29. Turpin A, el Amrani M, Bachet JB, Pietrasz D, Schwarz L, Hammel P. Adjuvant pancreatic cancer management: towards new perspectives in 2021. Cancers. 2020;12:3866.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JP, Ghaneh P, Rawcli E, Bassi C, Stocken DD, Cunningham D, O’Reilly D, Goldstein D, Robinson BA, Karapetis C, Scarfe A, Lacaine F, Sand J, Izbicki J, Mayerle J, Dervenis C, Oláh A, Butturini G, Lind PA, Middleton MR, Anthoney A, Sumpter K, Carter R, Büchle MK. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32:504–12.

    Article  PubMed  Google Scholar 

  31. Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O’Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB, Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE Group. FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–406.

    Article  CAS  PubMed  Google Scholar 

  32. Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Groot KB. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. Natl Cancer Inst. 2019;111:782–94.

    Article  Google Scholar 

  33. Padillo FJ, Ruiz-Rabelo JF, Cruz A, Perea MD, Tasset I, Montilla P, Tunez I, Muntane J. Melatonin and celecoxib improve the outcomes in hamsters with experimental pancreatic cancer. J Pineal Res. 2010;49:264–70.

    Article  CAS  PubMed  Google Scholar 

  34. Ruiz-Rabelo J, Vázquez R, Arjona A, Perea D, Montilla P, Túnez I, Muntané J, Padillo J. Improvement of capecitabine antitumoral activity by melatonin in pancreatic cancer. 2011;40:410–4.

    CAS  Google Scholar 

  35. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg. 2010;200:197–203.

    Article  PubMed  Google Scholar 

  36. Conroy T, Ducreux M. Adjuvant treatment of pancreatic cancer. Curr Opin Oncol. 2019;31:346–53.

    Article  CAS  PubMed  Google Scholar 

  37. Maréchal R, Bachet J-B, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology. 2012;143:664–74.

    Article  PubMed  Google Scholar 

  38. Puleo F, Nicolle R, Blum Y, Cros J, Marisa L, Demetter P, Quertinmont E, Svrcek M, Elarouci N, Iovanna J, Franchimont D, Verset L, Galdon MG, Devière J, de Reyniès A, Laurent-Puig P, Van Laethem JL, Bachet JB, Maréchal R. Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features. Gastroenterology. 2018;155:1999–2013.

    Article  PubMed  Google Scholar 

  39. Aung KL, Fischer SE, Denroche RE, Jang GH, Dodd A, Creighton S, Southwood B, Liang SB, Chadwick D, Zhang A, O’Kane GM, Albaba H, Moura S, Grant RC, Miller JK, Mbabaali F, Pasternack D, Lungu IM, Bartlett JMS, Ghai S, Lemire M, Holter S, Connor AA, Moffitt RA, Yeh JJ, Timms L, Krzyzanowski PM, Dhani N, Hedley D, Notta F, Wilson JM, Moore MJ, Gallinger S, Knox JJ. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin Cancer Res. 2018;24:1344–54.

    Article  CAS  PubMed  Google Scholar 

  40. Kaissis G, Ziegelmayer S, Lohöfer F, Steiger K, Algül H, Muckenhuber A, Yen HY, Rummeny E, Friess H, Schmid R, Weichert W, Siveke JT, Braren R. A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy. PLoS One. 2019;14(10):e0218642. https://doi.org/10.1371/journal.pone.0218642.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Hackert T. Surgery for pancreatic cancer after neoadjuvant treatment. Ann Gastroenterol Surg. 2018;2:413–8.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Inoue Y, Saiura A, Yoshioka R, Ono Y, Takahashi M, Arita J, Takahashi Y, Koga R. Pancreatoduodenectomy with systematic mesopancreas dissection using a supracolic anterior artery-first approach. Ann Surg. 2015;262:1092–101.

    Article  PubMed  Google Scholar 

  43. Sabater L, Cugat E, Serrablo A, Suarez-Artacho G, Diez-Valladares L, Santoyo-Santoyo J, Martín-Pérez E, Ausania F, Lopez-Ben S, Jover-Navalon JM, Garcés-Albir M, Garcia-Domingo MI, Serradilla M, Pérez-Aguirre E, Sánchez-Pérez B, Di Martino M, Senra-Del-Rio P, Falgueras-Verdaguer L, Carabias A, Gómez-Mateo MC, Ferrandez A, Dorcaratto D, Muñoz-Forner E, Fondevila C, Padillo J. Does the artery-first approach improve the rate of R0 resection in pancreatoduodenectomy? A multicenter, randomized, controlled trial. Ann Surg. 2019;270:738–46.

    Article  PubMed  Google Scholar 

  44. Mackay TM, Wellner UF, van Rijssen LB, Stoop TF, Busch OR, Groot Koerkamp B, Bausch D, Petrova E, Besselink MG, Keck T, Dutch Pancreatic Cancer Group and DGAV StuDoQ|Pancreas. Variation in pancreatoduodenectomy as delivered in two national audits. Br J Surg. 2019;106:747–55.

    Article  CAS  PubMed  Google Scholar 

  45. Kutlu OC, Vega EA, Salehi O, Lathan C, Kim S, Krishnan S, Stallwood C, Kozyreva O, Conrad C. Laparoscopic pancreatectomy for cancer in high volume centers is associated with an increased use and fewer delays of adjuvant chemotherapy. HPB (Oxford). 2020;25:S1365-182X(20)31146-1.

    Google Scholar 

  46. Kawabata Y, Hayashi H, Kaji S, Fujii Y, Nishi T, Tajima Y. Laparoscopic versus open radical antegrade modular pancreatosplenectomy with artery-first approach in pancreatic cáncer. Langenbecks Arch Surg. 2020;405:647–56.

    Article  PubMed  Google Scholar 

  47. van Hilst J, de Rooij T, Bosscha K, Brinkman DJ, van Dieren S, Dijkgraaf MG, Gerhards MF, de Hingh IH, Karsten TM, Lips DJ, Luyer MD, Busch OR, Festen S, Besselink MG, Dutch Pancreatic Cancer Group. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial. Lancet Gastroenterol Hepatol. 2019;4:199–207.

    Article  PubMed  Google Scholar 

  48. Nickel F, Haney CM, Kowalewski KF, Probst P, Limen EF, Kalkum E, Diener MK, Strobel O, Müller-Stich BP, Hackert T. Laparoscopic versus open pancreaticoduodenectomy: a systematic review and meta-analysis of randomized controlled trials. Ann Surg. 2020;271:54–66.

    Article  PubMed  Google Scholar 

  49. Shyr B-U, Chen S-C, Shyr Y-M, Wang S-E. Learning curves for robotic pancreatic surgery-from distal pancreatectomy to pancreaticoduodenectomy. Medicine (Baltimore). 2018;97:e13000.

    Article  PubMed  Google Scholar 

  50. Padillo J (Principal Investigator). Role of CTC’s spread during pancreaticoduodenectomy in patients with pancreatic and periampullary tumors (CETUPANC). ClinicalTrials.gov Identifier: NCT03340844.

  51. Qi B, Crawford AJ, Wojtynek NE, Holmes MB, Souchek JJ, Almeida-Porada G, Ly QP, Cohen SM, Hollingsworth MA, Mohs AM. Indocyanine green loaded hyaluronan-derived nanoparticles for fluorescence-enhanced surgical imaging of pancreatic cáncer. Nanomedicine. 2018;14:769–80.

    Article  CAS  PubMed  Google Scholar 

  52. Baiocchi GL, Diana M, Boni L. Indocyanine green-based fluorescence imaging in visceral and hepatobiliary and pancreatic surgery: state of the art and future directions. World J Gastroenterol. 2018;24:2921–30.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

To my colleagues of the University Hospital Virgen del Rocio HPB Unit and IBIS Pancreas Cancer Research Team: Gomez- Bravo MA, Suarez G, Alamo JM, Marin LM, Bernal C, Cepeda C, Beltran P, Calero F, Pereira S, Castillo JM, Macher H, Gallego I, Perez H, Borrero JJ.

Author information

Authors and Affiliations

  1. Department of General Surgery, Virgen del Rocio Hospital, Seville, Spain

    Javier Padillo-Ruiz

  2. Seville, Spain

    Javier Padillo-Ruiz

Authors
  1. Javier Padillo-Ruiz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Biliopancreatic Surgical Division, Hospital Universitario Virgen Macarena, Sevilla, Spain

    Juan Bellido Luque

  2. Biliopancreatic Surgical Division, Hospital Universitario Virgen Macarena, Sevilla, Spain

    Angel Nogales Muñoz

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Padillo-Ruiz, J. (2023). Introduction to Diagnosis and Treatment in Pancreatic Neoplasms. In: Bellido Luque, J., Muñoz, A.N. (eds) Recent Innovations in Surgical Procedures of Pancreatic Neoplasms. Springer, Cham. https://doi.org/10.1007/978-3-031-21351-9_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-21351-9_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-21350-2

  • Online ISBN: 978-3-031-21351-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation